Compare Immunovant Inc. Common Stock (IMVT) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Standard Lithium Ltd — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Standard Lithium Ltd trades at $1.62 (market cap $398.07M). The key difference: Immunovant Inc. Common Stock is far larger — about 15.7× Standard Lithium Ltd's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Standard Lithium Ltd for 23 Days on average.
| IMVT | SLI | |
|---|---|---|
Market Cap | $6.25B | $398.07M |
Volume | 1,755,411 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $44.96 | $5.65 |
52-Week Low | $17.03 | $1.61 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.35B | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported no revenue in 2025 and negative net income of -$48.40M, though recent quarters show improving EPS trends with two consecutive beats. Key developments include progress toward a final investment decision for the South West Arkansas lithium project by end-2026 and new customer offtake agreements.
The stock presents high-risk, high-reward potential with 100% analyst buy ratings and a $3.83 consensus price target offering 132% upside. However, significant execution risks remain as the company transitions to commercial production, with negative cash flow from operations and substantial capital requirements ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
